Phase 1/2 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Phase 1/2 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumors;   MET Gene Alterations
Intervention:   Drug: TPX-0022
Sponsor:   Turning Point Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 1, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments